Neumora Therapeutics, Inc. Segments Disclosure
14. Segment Reporting
Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment related to the development of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The Company’s (CEO) serves as the CODM.
The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company’s consolidated net loss. Through this analysis, the CEO assesses performance by comparing budget to actual results, and then decides how to allocate resources to invest in the Company’s research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets.
The table below is a summary of the segment loss, including significant segment expenses (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
|
(in thousands) |
|
|||||
Program expenses |
|
|
|
|
|
|
||
Navacaprant (NMRA-140) program |
|
$ |
(93,204 |
) |
|
$ |
(105,442 |
) |
M4 PAM programs |
|
|
(12,277 |
) |
|
|
(11,041 |
) |
NMRA-511 program |
|
|
(8,097 |
) |
|
|
(7,236 |
) |
Preclinical programs |
|
|
(10,987 |
) |
|
|
(5,776 |
) |
Research and development personnel-related costs |
|
|
(36,052 |
) |
|
|
(47,036 |
) |
General and administrative expense |
|
|
(60,091 |
) |
|
|
(62,537 |
) |
Acquired in-process research and development |
|
|
(5,000 |
) |
|
|
— |
|
Interest income |
|
|
8,344 |
|
|
|
19,933 |
|
Interest expense |
|
|
(3,219 |
) |
|
|
— |
|
Other segment items(1) |
|
|
(16,345 |
) |
|
|
(24,652 |
) |
Net loss |
|
$ |
(236,928 |
) |
|
$ |
(243,787 |
) |
(1) Includes other research and development costs, provision for income taxes, and other income (expense)
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Mar 3, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.